Reversible cardiomyopathies

Cardiology in Review

Volumn 15, Issue 4, 2007, Pages 178-183

  Nagarakanti, Rangadham ^a   Whellan, David ^b   Rubin, Sharon ^b   Mather, Paul J ^b,c  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Cardiomyopathies; Heart failure; Nonischemic; Outcomes; Reversible etiologies; Treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ASCORBIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DEFEROXAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; IMMUNOGLOBULIN; MELPHALAN; OCTREOTIDE; PROPRANOLOL; RADIOACTIVE IODINE; THALIDOMIDE; WARFARIN;

ACROMEGALY; ALCOHOLIC CARDIOMYOPATHY; AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CARDIOMYOPATHY; CLINICAL FEATURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FABRY DISEASE; HEALTH CARE COST; HEART AMYLOIDOSIS; HEART FAILURE; HEMOCHROMATOSIS; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; INCIDENCE; ISCHEMIC HEART DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREVALENCE; PRODUCTIVITY; PROGNOSIS; REVIEW; SIDEROSIS; TERATOGENICITY; THORAX RADIOGRAPHY; THYROID DISEASE;

ADULT; ALCOHOL DRINKING; CARDIOMYOPATHIES; CAUSALITY; CHILD; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; WORLD HEALTH;

EID: 34250729767     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31804c98b1     Document Type: Review

References (54)

1. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841-842.
2. Maron BJ, Towbin JA, Young JB, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816.
3. Tsuchihashi K, Ueshima K, Morii I, et al. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction - myocardial infarction investigations in Japan. J Am Coll Cardiol. 2001;38:11-18.
4. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the UK: data from the UK thalassaemia register. Lancet. 2000;355:2051-2052.
5. Shinbane JS, Wood MA, Ellenbogen KA, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-715.
6. Ro A, Frishman WH. Peripartum cardiomyopathy. Cardiol Rev. 2006;14:35-42.
7. Ansari AA, Neckelmann N, Wang YC, et al. Immunologic dialogue between cardiac myocytes, endothelial cells, and mononuclear cells. Clin Immunol Immunopathol. 1993;68:208-214.
8. Bybee KA, Kara T, Prasad A, et al. Transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med. 2004;141:858-865.
9. Olson LJ, Edwards WD, McCall JT, et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol. 1987;10:1239-1243.
10. Patel VB, Why HJ, Richardson PJ, et al. The effects of alcohol on the heart. Adverse Drug React Toxicol Rev. 1997;16:15-43.
11. Alexander CS. Cobalt-beer cardiomyopathy. A clinical and pathologic study of twenty-eight cases. Am J Med. 1972;53:395-417.
12. Klatsky AL. Alcohol-associated hypertension: when one drinks makes a difference. Hypertension. 2004;44:805-806.
13. Koshiyama H, Sellitti DF, Akamizu T, et al. Cardiomyopathy associated with Graves' disease. Clin Endocrinol (Oxf). 1996;45:111-116.
14. Drvota V, Janson A, Norman C, et al. Evidence for the presence of functional thyrotropin receptor in cardiac muscle. Biochem Biophys Res Commun. 1995;211:426-431.
15. Sellitti DF, Hill R, Doi SQ, et al. Differential expression of thyrotropin receptor mRNA in the porcine heart. Thyroid. 1997;7:641-646.
16. Fatourechi V, Edwards WD. Graves' disease and low-output cardiac dysfunction: implications for autoimmune disease in endomyocardial biopsy tissue from eleven patients. Thyroid. 2000;10:601-605.
17. Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation. 1995;92:2306-2317.
18. Perreault CL, Shannon RP, Komamura K, et al. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest. 1992;89:932-938.
19. Nakao S, Takenaka T, Tanaka H, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288-293.
20. Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971;44:1053-1061.
21. Pearson GD, Veille JC, Baughman KL, et al. Peripartum cardiomyopathy: National Heart, Lung and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183-1188.
22. Rizeq MN, Rickenbacher PR, Fowler MB, et al. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol. 1994;74:474-477.
23. Alvarez Navascues R, Marin R, Testa A, et al. Pre-eclampsia and peripartum cardiomyopathy: infrequent association. Nefrologia. 2001;21:84-87.
24. Felker GM, Thompson RE, Kasper EK, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-1084.
25. Urbano-Marquez A, Estruch R, Fernandez-Sola J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA. 1995;274:149-154.
26. Kasper EK, Agema WRP, Hutchins GM, et al. The cause of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol. 1994;23:586-590.
27. Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy - summary of a National Heart, Lung, and Blood Institute workshop. Am J Cardiol. 1992;69:1458-1466.
28. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18:33-39.
29. Damjanovic SS, Neskovic AN, Petakov MS, et al. High output heart failure in patients with newly diagnosed acromegaly. Am J Med. 2002;112:610-616.
30. Hradec J, Marek J, Poloniecki J, et al. Long-term echocardiographic follow-up of acromegalic heart disease. Am J Cardiol. 1993;72:205-210.
31. Frustaci A, Chimenti C, Setoguchi M, et al. Cell death in acromegalic cardiomyopathy. Circulation. 1999;99:1426-1434.
32. Howard RJ, Moe GW, Armstrong PW. Sequential echocardiographic Doppler assessment of left ventricular remodeling and mitral regurgitation during evolving experimental heart failure. Cardiovasc Res. 1991;260:H1903- H1911.
33. Bozkurt B, Alvarez RJ, Rosenblum WD, et al. Role of immunoglobulin in the treatment of postpartum cardiomyopathy. J Am Coll Cardiol. 1998;31:330-331.
34. Rahko PA, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol. 1986;8:436-440.
35. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127:348-355.
36. Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab. 2004;89:5308-5313.
37. Toft AD, Boon NA. Thyroid disease and the heart. Heart. 2000;84:455-460.
38. Sutton MSJ, Cole P, Plappert M, et al. Effects of subsequent pregnancy on left ventricular function in peripartum cardiomyopathy. Am Heart J. 1991;121:1776-1778.
39. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344:1567-1571.
40. Sharkey SW, Lesser JR, Maron MS, et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005;111:472-479.
41. Kurisu S, Sato H, Kawagoe T, et al. Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction. Am Heart J. 2002;143:448-455.
42. Nethala V, Brown EJ Jr, Timson CR, et al. Reversal of alcoholic cardiomyopathy in a patient with severe coronary artery disease. Chest. 1993;104:626.
43. Guillo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol. 1997;79:1276-1278.
44. Legrand V, Beckers A, Pham VT, et al. Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and trans-sphenoidal surgery. Eur Heart J. 1994;15:1286-1289.
45. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf). 2003;58:169-176.
46. Rajasoorya C, Holdway IM, Scott DJ, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol. 1994;41:95-102.
47. Yu YH, Bilezikian JP. Tachycardia-induced cardiomyopathy secondary to thyrotoxicosis: a young man with previously unrecognized Graves' disease. Thyroid. 2000;10:923-927.
48. Bertil-Olsson S, Blomstrom P, Sabel KG, et al. Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture. Am J Cardiol. 1984;53:1465-1466.
49. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563-570.
50. Rao PS, Najjir HN. Congestive cardiomyopathy due to chronic tachycardia: resolution of cardiomyopathy and antiarrhythmic drugs. Int J Cardiol. 1987;17:216-220.
51. Gillette PC, Wampler PG, Garson A, et al. Treatment of atrial automatic tachycardia by ablation procedures. J Am Coll Cardiol. 1985;6:405-409.
52. Nerheim P, Birger-Botkin S, Piracha L, et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110:247-252.
53. Vesole DH, Perez WS, Akasheh M, et al. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc. 2006;81:880-888.
54. Frustaci A, Chimenti C, Desnick RJ. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med. 2001;345:25-32.